VIII BIBLIOGRAFÍA

  1. Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds). Textbook of Rheumatology, 7th 2005. Philadelpia, WB Saunders.

    2.  

  2. Schellekens GA, de Jong BA, van den Hoogen FH et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273 –81.

    3.  

  3. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001 Jun;47(6):1089-93.

    4.  

  4. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.

    5.  

  5. Pincus T, Brooks RH, Callahan JF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count. Ann Intern Med 1994;120:26–34.

    6.  

  6. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, Emery P, Gough A, James D, Prouse P, Williams P, Winfield J. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Annals of the Rheumatic Diseases 61(4):335-40, 2002.

    7.  

  7. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12):907-16, 2001.

    8.  

  8. Nepom GT, Hansen JA, Nepom BS. The molecular basis for HLA class II associations with rheumatoid arthritis. J Clin Immunol. 1987;7:1-7.
  9. Nelson JL, Mickelson E, Masewicz S, Barrington R, Dugowson C, Koepsell T, et al. Dw14(DRB1*0404) is a Dw4-dependent risk factor for rheumatoid arthritis. Rethinking the "shared epitope" hypothesis. Tissue Antigens. 1991;38: 145-51.
  10. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006 Feb 9;354(6):610-21.
  11. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
  12. Houssiau FA. Cytokines in rheumatoid arthritis. Clin Rheumatol 1995;14:Suppl 2:10-3.

    13.  

  13. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor b in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.

    14.  

  14. Chikanza IC, Kingsley G, Panayi GS. Peripheral blood and synovial fluid monocyte expression of interleukin 1a and 1b during active rheumatoid arthritis. J Rheumatol 1995;22:600-6.

    15.  

  15. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.

    16.  

  16. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.

    17.  

  17. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.

    18.  

  18. Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum. 1976; 4:299-326.

    19.  

  19. Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J. 1973;2:96-100)

    20.  

  20. Smith J, Haynes M. Rheumatoid Arthritis - A Molecular Understanding. Ann Intern Med. 2002; 136:908-922.

    21.  

  21. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med. 2001;135: 279-95.

    22.  

  22. Klippel J, Weyand C, Wortmann R. Primer on the Rheumatic Diseases. 11th ed. 1997 (Edición en Español) pg. 186 - 193

    23.  

  23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.

    24.  

  24. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940; 17:172.

    25.  

  25. Rose HM, Ragan C, Pearce E, et al. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1948; 68:1.

    26.  

  26. Bobbio-Pallavicini F, Alpini C, Caporali R et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6:R264 –72.

    27.  

  27. Nissinen R, Leirisalo-Repo M, Peltomaa R et al. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:681 –7.

    28.  

  28. Alessandri C, Bombardieri M, Papa N et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63:1218 –21.

    29.  

  29. de Rycke L, Verhelst X, Kruithof E et al. Rheumatoid factor, but not anti-citrullinated protein antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2004; 64:299 –302.

    30.  

  30. Caramaschi P, Biasi D,Tonolli E et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005 Nov; 26(1):58-62.

    31.  

  31. Raskin JB, White RH, Jackson JE, et al: Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123:344.

    32.  

  32. Moreland LW, Baumgartner SW, Schiff MH: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) fusion protein. N Engl J Med 1997; 337:141.

    33.  

  33. Alarcon GS: Methotrexate use in rheumatoid arthritis: a clinician's perspective. Immunopharmacology 2000; 47:259.

    34.  

  34. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.

    35.  

  35. Edwards JC,Szczepanski L,Szechinski J et al .Ef .cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.N Engl J Med 2004;350:2572 –81.

    36.  

  36. Edwards JC,Cambridge G.Prospects for B-cell-targeted therapy in autoimmune disease.Rheumatology 2005;44:151 –6.J Exp Med 1991;173:487 –9.

    37.  

  37. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis. 1964 Jul; 23:302-5.

    38.  

  38. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979 Jul 14;2(6182):97-9.

    39.  

  39. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan; 45(1): 20-5.

    40.  

  40. Wiik AS, van Venrooij WJ. The Use of Anti-cyclic Citrullinated Peptide (anti-CCP) Antibodies in AR. ACR Hotline 2003

    41.  

  41. Schellekens GA,Visser H,de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155 –63.

    42.  

  42. Zendman AJ, Vossenaar ER,van Venrooij WJ. Autoantibodies to citrullinated (poly) peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004;37:295 –9.

    43.  

  43. Rantapaä-Dahlqvist S, de Jong BA,Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741 –9.

    44.  

  44. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709 –15.

    45.  

  45. van Gaalen FA, Visser H,Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first-and second anti-cyclic citrullinated peptides autoantibody (CCP1 and CCP2) tests for rheumatoid arthritis. Ann Rheum Dis 2005 Oct;64(10):1510-2

    46.  

  46. van Venrooij WJ,Hazes JM,Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002;60:383 –8.

    47.  

  47. Pinheiro GC,Scheinberg MA,Aparecida da Silva M,Maciel S.Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003;139:234 –5.

    48.  

  48. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab 2002;21:34 –6.

    49.  

  49. Vallbracht I, Rieber J, Oppermann M et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63:1079 –84.

    50.  

  50. Kroot EJ,de Jong BA,van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831 –5.

    51.  

  51. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67 –8.

    52.  

  52. Wener MH,Hutchinson K,Morishima C,Gretch DR.Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.Arthritis Rheum 2004;50:2305 –8.

    53.  

  53. Salvador G,Gomez A, Vinas O et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?. Rheumatology 2003; 42:972 –5.

    54.  

  54. Gottenberg JE, Mignot S, Nicaise-Rolland P et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren ’s syndrome. Ann Rheum Dis 2004;64:114 –7.

    55.  

  55. Vander Cruyssen B, Hoffman IE, Zmierczak H et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145 –9.

    56.  

  56. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239 –62.

    57.  

  57. Kastbom A, Strandberg G, Lindroos A,Skogh T. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project).Ann Rheum Dis 2004;63:1085 –9.

    58.  

  58. Gossec L, Dougados M, Goupille P et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004;63:675 –80.